Chiesi Ventures also aim to accelerate the expansion of the Chiesi network in the US among universities, venture capital investors, rare disease patient organizations and entrepreneurial companies developing treatments for rare diseases. (aurabiosciences.com)
Last week, Sanofi agreed to buy U.S. haemophilia specialist Bioverativ for $ 11.6 billion, its biggest deal for seven years and a major play to strengthen its presence in treatments for rare diseases. (cnbc.com)
Streamlining the regulatory process for developing genetic and other treatments for rare diseases, recognizing the time - consuming difficulty of acquiring a critical mass of patients for clinical trials for disorders affecting very few people. (sciencedaily.com)